Introduction
There is no doubt that sodium cromoglycate (SCG) is of value in the management of childhood asthma (Chai et al., 1970; Smith and Devey, 1968) . Silverman et al. (1972) showed that 71% of their patients not taking steroids were effectively controlled by SCG. Godfrey, Balfour-Lynn and Konig (1975) (Dickson et al., 1973; Frears, Wilson and Friedman, 1973; Howard and Jacoby, 1974) . Bethamethasone valerate was noted by Kuzemko et al. (1974) to be more effective than sodium cromoglycate when both were given twice daily. Hiller and Milner (1975) reported that patients who were not well controlled on sodium cromoglycate gained no greater benefit from the addition of betamethasone valerate than was gained by giving the steroid alone.
The clinical response of asthmatic children under controlled conditions has been studied in a trial designed as a double-blind, cross-over study to compare betamethasone valerate (BV) with sodium cromoglycate (SCG) by inhalation in the treatment of children whose asthma was not controlled satisfactorily on bronchodilator therapy and who were, therefore, under consideration for more intensive treatment with SCG or corticosteroids.
Methods
With informed parental consent, twenty children took part in the trial which was double-blind. They were selected on the basis that their asthma was inadequately controlled on regular bronchodilator therapy. All the children had reversible mucosal or airways obstruction and evidence of atopy. The mean age was 9-7 years (range 6-7-13-7 years), the mean height was 133 cm (range 114-153 cm), and mean weight was 28-1 kg (range 200-37-5 kg). The mean peak expiratory flow rate (PEFR) was 52% of the predicted normal value (Polgar and Promadhat, 1971 Otherwise, there were no differences between the behaviour of these two sub-groups. The differences in mean daily PEFR between the two treatments were 64 I/min in sub-group A and 61 I/min in subgroup B. Sub-group A, after the initial placebo period, was put on BV. The mean daily PEFR rose rapidly during the first 14-day period of BV and the elevation was sustained in the second 14-day period. The mean daily PEFR fell rapidly when the treatment was changed to SCG and the lower level was then maintained throughout both 14-day periods.
Sub-group B, after the initial placebo period, was put on SCG. There was a less marked elevation of the mean daily PEFR during the first 14-day period of SCG but this elevation was not sustained in the second 14-day period. When the patients were put on BV, there was a rapid elevation of the mean daily PEFR and during the second 14-day period, the plateau appeared to have been reached. There was no difference between the mean daily PEFR of each sub-group during BV therapy whether one considers the first fourteen day period, the second, or the whole 28 days. Similarly there were no differences between the two sub-groups when treated with SCG.
Discussion and conclusions
Sodium cromoglycate appeared to be more effective during the waking hours when the patient was having his inhalation, but its effect did not persist through the sleeping hours. Betamethasone valerate, on the other hand, appeared to be effective in reducing asthma throughout the whole 24 hr. The comments made by parents, that the children played more strenuous games during BV confirmed that exercise-induced bronchoconstriction disappeared after prolonged therapy (Hodgson, McPherson and Friedman, 1974) but not after single doses (Hills, Davies and Geary, 1974) and suggest that the effect of BV is either more pronounced or more sustained that that of SCG. Certainly mean PEFRs were greater with BV therapy.
Response to BV was generally detectable by twice daily PEFR measurements within 24 hr and continued to increase over at least the ensuing few days. In a study of eleven children, Hiller and Milner (1975) At a dose of 800 ,ug/day for 4 weeks BV did not seem to affect the children's response to tetracosactrin. This is in agreement with reports by Friedman and Frears (1974) and by Taylor and Norman (1974) .
Candida albicans did not cause any clinical problems and rarely seems to do so in children receiving steroid aerosols Hiller and Milner (1975) were unable to demonstrate additional benefit of the combination over BV alone.
In conclusion, this short-term trial has shown that inhaled betamethasone valerate at a fixed dose (200 ,g q.i.d.) is as well tolerated and as rapidly effective as sodium cromoglycate (20 mg q.i.d.) but that it provides a superior degree of control of asthma in children who are responding sub-optimally to bronchodilators.
